Stryker SYK recently received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, the new system is designed to enhance surgical power, precision and workflow efficiency. The first clinical cases are expected to begin in October, with a full commercial launch anticipated later this fall.
The launch marks another step in Stryker’s efforts to strengthen its neurosurgical portfolio through product innovation and surgeon-focused technologies. The new platform could support customer engagement and create revenue growth opportunities as commercialization progresses. However, near-term financial contribution will likely depend on the pace of adoption, demand from hospitals and surgical centers, and the company's ability to translate the product's performance improvements into broader market penetration.
SYK Stock Trend Following the News
Following the announcement on Oct. 14, SYK stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 13.4% compared with the industry’s 13.4% decline and the S&P 500’s 12% rise.
Stryker’s launch of Sonopet 3 could support its long-term growth by strengthening its neurosurgical portfolio and reinforcing its focus on surgeon-driven innovation. The platform’s enhanced power, precision and workflow integration could improve its appeal to surgeons and healthcare providers, supporting customer retention and adoption across surgical settings. Over time, successful commercialization could create incremental revenue opportunities and strengthen Stryker’s competitive positioning in the neurosurgery market.
SYK currently has a market capitalization of $108.02 billion.
Image Source: Zacks Investment Research
More on the News
Sonopet 3 was developed with feedback from hundreds of surgeons, with design improvements guided by their requirements for greater power, better ergonomics and enhanced integration in demanding surgical environments. The platform incorporates RISE, or Reimagined Integrated Surgical Experience, which is designed to support a more connected surgical workflow, and Pulse Control, which gives surgeons additional control over the removal of hard and soft tissues. These features are intended to improve usability and help streamline surgical workflows across different settings. According to Stryker, the enhancements reflect its focus on incorporating customer feedback into product development and advancing its neurosurgical technologies.
Stryker expects the first clinical cases using Sonopet 3 to begin in October, ahead of a full commercial launch anticipated later in fall 2026. The upcoming rollout will be an important step in gauging the platform's initial reception among surgeons and healthcare providers. Successful adoption could strengthen Stryker's competitive position in neurosurgery and create opportunities to deepen relationships with hospitals and surgical teams.
However, the company has not disclosed specific sales targets or the expected financial contribution from Sonopet 3. Its commercial impact will therefore depend on the pace of market adoption and the extent to which the new platform translates its performance and workflow enhancements into sustained customer demand.
Industry Prospects Favoring the Market
According to data provided by Persistence Market Research, the global neurosurgery market size is expected to be valued at $5.9 billion in 2026 and projected to reach $8.4 billion by 2033, expanding at a CAGR of 5.1% between 2026 and 2033.
The market is driven by the rise in global burden of neurological conditions, including traumatic brain injury, stroke, brain tumors and epilepsy, combined with rapid innovation in minimally invasive neurosurgical techniques, neuro-interventional devices and stereotactic radiosurgery systems.
Other News
In September, SYK announced an expansion of its Foot & Ankle portfolio, launching Prophecy Surgical Planning for the Incompass Total Ankle System and introducing Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.
SYK’s Zacks Rank & Key Picks
Currently, SYK carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI.
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).